A further thought playing to NEU and Acadia strengths in an ongoing partnership:
* NEU would act as the Ph2 clinical trial factory for all new Trof and 2591 indications in North America and ROW
* Acadia with its infrastructure and experience would act at the Ph3 clinical trial, regulatory approval, sales and support factory for NA and ROW
Clear set of roles and responsibilities.
Risks and rewards for both
GLTA
Ann: Neuren and Acadia expand global partnership for trofinetide, page-89
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |